Expert review of hematology · 2026
Advances in the treatment of large granular lymphocytic leukemia.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Guégan Mathilde, Lamy Thierry
Аннотация
INTRODUCTION: Large granular lymphocytic leukemia (LGLL) is a rare lymphoproliferative disease characterized by marked phenotypic, molecular, and clinical heterogeneity. Recent therapeutic advances and emerging clinical data warrant a comprehensive overview of current and evolving treatment strategies.
AREAS COVERED: This review summarizes current and future therapeutic approaches in LGLL, including criteria for treatment initiation and response assessment. The literature was identified through a comprehensive search of PubMed up to November 2025. We address the evolving positions of the three main immunosuppressive agents - methotrexate, cyclophosphamide and ciclosporin A - along with other strategies such as chemotherapy, immunotherapy, and hematopoietic stem cell transplantation. In addition, we highlight emerging targeted therapies driven by advances in the understanding of LGLL pathophysiology. Ongoing clinical trials registered on ClinicalTrials.gov and novel agents likely to expand the therapeutic landscape of LGLL are also discussed.
EXPERT OPINION: LGLL management is undergoing a paradigm shift with the emergence of multiple targeted therapeutic approaches. Future progress will depend on better prognostic stratification, better integration of disease and patient heterogeneity, and the development of personalized treatment strategies, potentially supported by molecular monitoring.
AREAS COVERED: This review summarizes current and future therapeutic approaches in LGLL, including criteria for treatment initiation and response assessment. The literature was identified through a comprehensive search of PubMed up to November 2025. We address the evolving positions of the three main immunosuppressive agents - methotrexate, cyclophosphamide and ciclosporin A - along with other strategies such as chemotherapy, immunotherapy, and hematopoietic stem cell transplantation. In addition, we highlight emerging targeted therapies driven by advances in the understanding of LGLL pathophysiology. Ongoing clinical trials registered on ClinicalTrials.gov and novel agents likely to expand the therapeutic landscape of LGLL are also discussed.
EXPERT OPINION: LGLL management is undergoing a paradigm shift with the emergence of multiple targeted therapeutic approaches. Future progress will depend on better prognostic stratification, better integration of disease and patient heterogeneity, and the development of personalized treatment strategies, potentially supported by molecular monitoring.